Is Pfizer Stock in Trouble?

One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Even though it posted some decent earnings numbers, investors can't shake the fear that the business is facing daunting headwinds that could send its $145 billion valuation lower in the months and years ahead. And while the markets have done well overall, shares of Pfizer are down some 11% this year.

Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the business right now?

Are investors overly concerned about vaccine demand?

Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 billion in 2022), for many investors, it's still seen as a stock whose best days may be behind it. Demand for its COVID vaccine is waning, significantly, and some investors may worry about a potential change in vaccine policy under the incoming Trump administration.

There's no denying that the recent election results do appear to be weighing on investors, as Pfizer's stock has hit a new low since then. Today, the stock is trading at a heavily discounted forward price-to-earnings multiple (based on analyst estimates) of less than 9, which suggests that investors are feeling a bit concerned about Pfizer's future.

Through the first nine months of the year, Pfizer has generated revenue of $45.9 billion, up 2% overall. While that seems modest, it's not a bad growth rate when you factor in a steep decline from COVID vaccine sales. Comirnaty, the company's COVID vaccine, has generated sales of less than $2 billion, which represents a year-over-year decline of 66%.

Stronger results from its specialty care and oncology segments have helped Pfizer overcome headwinds from the vaccine side of its operations.

Vaccines and COVID sales aren't the reasons to invest in Pfizer

There could be greater declines in vaccine and COVID sales in the future for Pfizer, regardless of government policy. And that's because attitudes have shifted in recent years, some people have become more skeptical about vaccines, and unless COVID becomes a significant health concern again, sales could continue to decline. But given the stock's depressed valuation, I believe those risks have already been priced into its share price.

At this stage, if you're investing in Pfizer, it's because you're optimistic about its growth opportunities outside vaccine-related revenue. The big growth opportunity may be in oncology, especially with Pfizer investing $43 billion to acquire Seagen, which makes antibody-drug conjugates that are more targeted treatment options than chemotherapy. Pfizer has been acquiring multiple businesses in recent years, and with a more diverse pipeline of drugs, those moves can offset the effects that looming patent cliffs and the decline in COVID sales will have on its operations in the long run.

Another potentially massive opportunity for Pfizer is in the weight loss market, where it's working on a once-daily pill, which could unlock a significant growth catalyst for the business. The pill, danuglipron, has been showing promise in early-stage trials, and it could be one of the first oral weight loss treatments to obtain approval from regulators in the near future.

Pfizer faces some risk, but the stock could still provide excellent value

There's a fair bit of uncertainty around Pfizer's business in both the near term and over the long haul. But with 108 drug candidates in its portfolio as of Oct. 29 and the company investing heavily into its long-term growth, there are still many potential catalysts out there that can help the business expand its operations and earnings in the future.

At a its discounted price, investors can also secure a good margin of safety for the stock, which can help to reduce some of the overall risk that comes with owning it. It may not be a suitable option for all risk-averse investors, but it's also not a stock in deep trouble, either. If you're OK with some uncertainty, this can be a good, undervalued investment to hang on to for the long term, as Pfizer's stock has the potential to deliver some great returns.

Should you invest $1,000 in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $839,060!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of November 25, 2024

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.